Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson's Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Liu, Yang ^a   Guo, Yubo ^a   An, Sai ^a   Kuang, Yuyang ^a   He, Xi ^a   Ma, Haojun ^a   Li, Jianfeng ^a   Lv, Jing ^b   Zhang, Ning ^b   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

^b PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DENDIGRAFT POLYLYSINE; NANOPARTICLE; PLASMID DNA; POLYLYSINE; RABIES VIRUS GLYCOPROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMPLEX FORMATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; ENZYME INHIBITION; GENE SILENCING; GENE VECTOR; IN VIVO STUDY; LOCOMOTION; MALE; MOLECULAR IMAGING; NERVE CELL DEGENERATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; RAT; RNA INTERFERENCE; TRANSCYTOSIS;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; CASPASE 3; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLYCOPROTEINS; MALE; MOTOR ACTIVITY; NANOPARTICLES; PARKINSON DISEASE; PERMEABILITY; POLYLYSINE; RABIES VIRUS; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRAL PROTEINS;

EID: 84877660877     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062905     Document Type: Article

References (28)

1. Lo BC, Ridet JL, Schneider BL, Deglon N, Aebischer P, (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 16: 10813-10818.
2. Denyer R, Douglas MR (2012) Gene therapy for Parkinson's disease. Parkinsons Dis 757305.
3. Fahn S (2006) Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl 71: 1-15.
4. Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, et al. (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 23: 10302-10312.
5. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH (2010) Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 237-264.
6. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 12: 1301-1306.
7. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, et al. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 16: 7006-7015.
8. Sherer TB, Betarbet R, Greenamyre JT, (2002) Environment, mitochondria, and Parkinson's disease. Neuroscientist 3: 192-197.
9. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, et al. (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 6: 2875-2880.
10. Carvey PM, Punati A, Newman MB, (2006) Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 3: 239-250.
11. Yuan J, Yankner BA, (2000) Apoptosis in the nervous system. Nature 6805: 802-809.
12. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, et al. (2011) Caspase signalling controls microglia activation and neurotoxicity. Nature 7343: 319-324.
13. Wood MJ, Trulzsch B, Abdelgany A, Beeson D (2003) Therapeutic gene silencing in the nervous system. Hum Mol Genet R279-R284.
14. Gao Y, Chen L, Zhang Z, Chen Y, Li Y, (2011) Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 6: 1738-1747.
15. Cottet H, Martin M, Papillaud A, Souaid E, Collet H, et al. (2007) Determination of dendrigraft poly-L-lysine diffusion coefficients by taylor dispersion analysis. Biomacromolecules 10: 3235-3243.
16. Tsogas I, Theodossiou T, Sideratou Z, Paleos CM, Collet H, et al. (2007) Interaction and transport of poly(L-lysine) dendrigrafts through liposomal and cellular membranes: the role of generation and surface functionalization. Biomacromolecules 10: 3263-3270.
17. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 7149: 39-43.
18. Lou J, Gasche Y, Zheng L, Critico B, Monso-Hinard C, et al. (1998) Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur J Immunol 28: 3989-4000.
19. Kirik D, Rosenblad C, Bjoklund A, (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
20. Lee K, Zhao X, Im J, Grosso H, Jang W, et al. (2012) Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 7: e29935.
21. Huang R, Ke W, Liu Y, Wu D, Feng L, et al. (2010) Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 1-2: 123-130.
22. Lu X, Ma L, Ruan L, Kong Y, Mou H, et al. (2010) Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 46.
23. Liu Y, Hu Y, Guo Y, Ma H, Li J, et al. (2012) Targeted imaging of activated caspase-3 in the central nervous system by a dual functional nano-device. J Control Release 163: 203-210.
24. Mattson MP, (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2: 120-129.
25. Sherer TB, Betarbet R, Kim JH, Greenamyre JT, (2003) Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2: 87-90.
26. Ravenstijn PG, Drenth HJ, O'Neill MJ, Danhof M, de Lange EC (2012) Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease. Fluids Barriers CNS 4.
27. Burke RE (2010) Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res 79-97.
28. Bashkatova V, Alam M, Vanin A, Schmidt WJ, (2004) Chronic administration of rotenone increases level of nitric oxide and lipid peroxidation products in rat brain. Exp Neurol 186: 235-241.